Faricimab▼ in Neovascular Age-Related Macular Degeneration: Year 2 Efficacy, Safety and Durability Results From the Phase 3 TENAYA and LUCERNE Trials
This presentation reports week 112 results, including for the Asian country subgroup, from the phase 3 TENAYA and LUCERNE trials of faricimab▼, a bispecific antibody that independently binds and neutralizes both Ang-2 and VEGF-A, in patients with neovascular age-related macular degeneration. TENAYA and LUCERNE investigated the efficacy, safety, and durability of faricimab▼, administered at individualized treatment intervals of up to every 16 weeks compared with aflibercept administered every 8 weeks.